New Delhi, Mar 10: A national consensus published in the Journal of the Association of Physicians of India (2026) has redefined the role of Semaglutide in cardiology, recognizing it as a key therapy for addressing cardiovascular disease, kidney dysfunction, and metabolic disorders. The recommendations were developed by a panel of India’s leading cardiologists, highlighting a shift from semaglutide’s earlier use in blood sugar management toward its broader role in modifying the progression of heart-related conditions.
Addressing India’s Unique Cardiovascular Risk Profile
The consensus emphasizes the need to address the distinctive “Indian phenotype,” where cardiovascular and metabolic risks appear earlier and at significantly lower body mass index (BMI) levels compared to Western populations. This vulnerability is largely driven by higher levels of visceral fat—fat stored around internal organs—and increased insulin resistance, even among individuals who may not appear obese according to traditional standards.
To improve early detection and prevention, the expert panel recommends prioritizing waist circumference rather than relying solely on BMI. According to the consensus, waist circumference exceeding 90 cm in men and 80 cm in women should be considered a key indicator for early intervention to prevent heart attacks and strokes.
Clinical Evidence Supporting Semaglutide
The consensus draws on findings from major clinical studies, including the SELECT Trial, which demonstrated that semaglutide therapy can reduce the risk of major cardiovascular events such as heart attacks and strokes by 20 percent. Notably, approximately two-thirds of this benefit is attributed to reductions in internal inflammation rather than weight loss alone.
In addition to cardiovascular benefits, semaglutide has shown potential to support kidney and liver health while regulating biological hunger signals in the brain, helping patients manage appetite and sustain weight loss more naturally.
Patient Groups Recommended for Therapy
The consensus identifies several patient groups that may benefit from treatment with semaglutide:
-
Heart patients with obesity: Adults with established cardiovascular disease who are overweight or obese, even without diabetes.
-
Heart failure management: Patients with obesity-related heart failure (HFpEF) to improve breathing capacity and daily activity.
-
Multiple metabolic conditions: Individuals with obesity combined with diabetes, hypertension, or lipid abnormalities.
-
High-risk South Asian patients: Those showing early metabolic damage despite relatively lower BMI levels.
-
Sustained weight management: Patients requiring meaningful and sustained weight loss.
-
Secondary prevention: Individuals with existing heart disease whose symptoms are worsened by excess body weight.
Recommended Dosing Roadmap
To ensure safe and effective use, the consensus provides a structured five-step dosing pathway designed to help patients gradually adapt to the therapy while minimizing gastrointestinal side effects:
-
Weeks 1–4: Initiation at 0.25 mg weekly
-
Weeks 5–8: Increase to 0.5 mg weekly
-
Weeks 9–12: Increase to 1.0 mg weekly
-
Weeks 13–16: Increase to 1.7 mg weekly
-
Week 17 onwards: Maintenance dose of 2.4 mg weekly, with 1.7 mg as an alternative if the higher dose is not tolerated
If a patient experiences difficulty tolerating a dose, the escalation may be delayed for more than four weeks to ensure safety and comfort.
A Long-Term Approach to Cardiometabolic Health
Recognizing obesity as a chronic and relapsing biological condition, the consensus positions semaglutide as a long-term foundational therapy rather than a short-term treatment option. By incorporating semaglutide into routine cardiology care, clinicians may be able to address the underlying metabolic drivers that contribute to India’s growing burden of cardiovascular disease.
The consensus underscores the importance of integrating modern metabolic therapies into cardiovascular care strategies, with the goal of reducing long-term risks and improving overall patient outcomes across India.
|
